Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

15.2%

14 terminated/withdrawn out of 92 trials

Success Rate

82.1%

-4.5% vs industry average

Late-Stage Pipeline

39%

36 trials in Phase 3/4

Results Transparency

75%

48 of 64 completed trials have results

Key Signals

4 recruiting48 with results12 terminated

Enrollment Performance

Analytics

Phase 2
41(46.1%)
Phase 3
32(36.0%)
Phase 1
9(10.1%)
Phase 4
4(4.5%)
N/A
3(3.4%)
89Total
Phase 2(41)
Phase 3(32)
Phase 1(9)
Phase 4(4)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (92)

Showing 20 of 92 trials
NCT05778188Phase 2Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Role: collaborator

NCT05579327Phase 3Completed

Withdrawal of Tiratricol Treatment in Males With Monocarboxylate Transporter 8 Deficiency (MCT8 Deficiency)

Role: collaborator

NCT07065240Phase 2Recruiting

A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)

Role: collaborator

NCT07161700Phase 2Enrolling By Invitation

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Role: collaborator

NCT07453069Phase 2Not Yet Recruiting

Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Dysbiosis Undergoing a Mock Frozen Embryo Transfer Cycle

Role: collaborator

NCT02446821Phase 2Completed

Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception

Role: collaborator

NCT01223313Not ApplicableCompleted

A Multicenter, Open-Label, Non-Comparative Study of the Safety and Contraceptive Efficacy of the Woman's Condom

Role: lead

NCT00455156Phase 3Completed

Study of the Safety, Efficacy and Cycle Control of a Contraceptive Vaginal Ring

Role: lead

NCT01166412Phase 1Completed

A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG)

Role: lead

NCT03296098Phase 2Withdrawn

Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

Role: lead

NCT02754687Phase 1Completed

Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men

Role: lead

NCT03432416Phase 2Completed

Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring

Role: lead

NCT03455075Phase 2Completed

Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men

Role: lead

NCT07222228Phase 2Not Yet Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Levonorgestrel Butanoate for Female Contraception

Role: lead

NCT04143659Phase 1Active Not Recruiting

A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception

Role: lead

NCT04636229Phase 3Completed

Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee

Role: collaborator

NCT07169162Phase 4Withdrawn

ADZENYS XR-ODT™ in Children (4 to <6 Years) Diagnosed With Attention-deficit/Hyperactivity Disorder

Role: collaborator

NCT05026177Phase 3Terminated

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Role: collaborator

NCT07116694Phase 2Active Not Recruiting

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder

Role: collaborator

NCT05721235Phase 4Completed

A Safety/Tolerability and PK Study With Azstarys® in Children With ADHD

Role: collaborator